Sanofi to review its new eczema drug amlitelimab - Meet them in May

Corvus shares nearly triple on positive data for eczema pill

An immune drug developer raises $50M to finance its eczema drug testing

Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study - Meet them in May

J&J eyes $100B in sales amid gains for cancer, immune drugs - Meet them in May

Alumis soars as TYK2 drug hits mark in psoriasis trials - Meet them in May

Galapagos TYK2 drug hits goal in one trial, misses in another

Takeda says $4B TYK2 drug succeeds in large psoriasis studies

Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study

Connect’s Dupixent challenger hits the mark in phase 3 eczema trial

Apogee strengthens case for longer-lasting eczema drug

Dana Novac

Senior Director - Medical Torqur

Wednesday 20th May 2026

Tackling Actinic Keratosis Via a New Mechanism of Action: Bimiralisib, a Topical PI3K/mTOR Inhibitor for Precancerous Dermatological Indications

1:30 pm

Upregulation of the PI3K/mTOR signaling pathway is a key driver of actinic keratosis (AK) pathogenesis, highlighting PI3K and mTOR as attractive, novel targets for disease intervention
Translational disease models evaluating skin pharmacokinetics, pathway regulation and efficacy demonstrate strong proof of concept for the topical dual-PI3K/mTOR inhibitor bimiralisib in AK
Topical bimiralisib shows compelling efficacy and favorable tolerability, supporting transition into pivotal Phase 3 trials in AK